Search

Cutting-edge practice in glaucoma care: what, how and why?

More effective treatments and drug delivery modalities, implantable minimally invasive glaucoma surgical (MIGS) devices, as well as accelerating clinical research programmes, will transform the surgical and clinical management of glaucoma in the near future. There is also an ever-greater emphasis...

Management of retinal diseases: highlights from the AAO 2019 Retina Subspecialty Day Meeting

The author highlights current debate, opinion and late breaking developments in the management of retinal diseases. The American Academy of Ophthalmology’s 2019 Retina Subspecialty Day Meeting was held on 11-12 October, 2019 in San Francisco, USA. Established and emerging innovative...

Hot debates in medical retina and imaging: Perspectives from the Controversies in Ophthalmology 2020 virtual conference

Controversies in medical retina and imaging were debated during the Controversies in Ophthalmology 2020 virtual conference held during two mid-day scientific sessions on 27 and 28 March 2020. The author recounts key perspectives and presents viewpoint recommendations from the Vision...

Emerging developments in dry eye

An estimated 344 million people worldwide suffer from dry eye [1]. This chronic syndrome is characterised by a vicious cycle of tear film hyperosmolarity, tear instability and corneal stress, leading to increased friction, inflammation, ocular surface damage and decreased visual...

Designing ophthalmology services - Part 1: How do we address the queues in a clinic?

This first of a three-part series shows how systems engineering can be used to correctly diagnose and address the causes of delays in a clinic. The second article, which will be featured in the April/May 2020 issue, describes how to...

Regulatory drug evaluations and expedited review initiatives: EU and US perspectives

The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...

Blinking blepharitis has a lot to answer for…

Never ignore the small things’…someone once said. There is no doubt blepharitis is one of the most common eye conditions encountered daily, but with the typical pressures of a busy outpatient department, the management of more obvious, sight-threatening conditions necessarily...

Diary from my elective: a Parisian experience

The author explains how a research institute’s dedication to multidisciplinary collaboration helped him to discover a passion for academic ophthalmology. The elective aspect to the final year of a medical degree, through its change of scenery and immersion into another...

Unconscious bias (part 2)

Does unconscious bias exist, and does training help to reduce discriminatory behaviour? Clare Inkster questions her role as a trainer. I read Gwyn Williams’ Learning Curve article on this topic a few months ago with interest, and as someone who...

See sweet to C-suite: Peter Holland

See also - See sweet to C-suite: Imran Rahman In this three-part conversation series, Co-editor David Lockington speaks with highly influential individuals about their journey to the top, with advice for the next generation of leaders. Part One: David speaks...

Demodex blepharitis: A transatlantic comparison of treatments available in the UK and US

Demodex blepharitis is widely recognised among eyecare professionals as an important cause of chronic lid margin inflammation, dry eye and ocular surface diseases. The characteristic feature for diagnosis is the presence of waxy deposit at the lash bases on slit...